Intestinal, but not hepatic, ChREBP is required for fructose tolerance
Mi-Sung KimInna AstapovaSarah N. FlierSarah Anissa HannouLudivine DoridotAshot SargsyanHenry H. KouAlan J. FowlerGuosheng LiangMark A. Herman
84
Citation
37
Reference
10
Related Paper
Citation Trend
Abstract:
Increased sugar consumption is a risk factor for the metabolic syndrome including obesity, hypertriglyceridemia, insulin resistance, diabetes, and nonalcoholic fatty liver disease (NAFLD). Carbohydrate responsive element–binding protein (ChREBP) is a transcription factor that responds to sugar consumption to regulate adaptive metabolic programs. Hepatic ChREBP is particularly responsive to fructose and global ChREBP-KO mice are intolerant to diets containing fructose. It has recently been suggested that ChREBP protects the liver from hepatotoxicity following high-fructose diets (HFrDs). We directly tested this hypothesis using tissue-specific ChREBP deletion. HFrD increased adiposity and impaired glucose homeostasis in control mice, responses that were prevented in liver-specific ChREBP-KO (LiChKO) mice. Moreover, LiChKO mice tolerated chronic HFrD without marked weight loss or hepatotoxicity. In contrast, intestine-specific ChREBP-KO (IChKO) mice rapidly lost weight after transition to HFrD, and this was associated with dilation of the small intestine and cecum, suggestive of malabsorption. These findings were associated with downregulation of the intestinal fructose transporter, Slc2a5, which is essential for fructose tolerance. Altogether, these results establish an essential role for intestinal, but not hepatic, ChREBP in fructose tolerance.Keywords:
Carbohydrate-responsive element-binding protein
Objective To investigate the epidemiology of fatty liver,metabolic syndrome,and their relationgship in Sinopec Zhenhai Refining Chemical Company(ZRCC).Methods 9543 people for health examination were chosen to observe their data of general imformation,physical examination,biochemical parameter.Fatty liver was diagnosed according to two dimension ultrasound.Metabolic syndrome was diagnosed according to 2005 IDF criteria.Results Of 9543 people,1177 were diagnosed as fatty liver,and the prevalence of fatty live was 12.3%;1289 were diagnosed as metabolic syndrome,and the prevalence of metabolic syndrome was 13.6%.The prevalence of both was increased with aging(0.05).The prevalence of fatty liver in people with metabolic syndrome was higher than that in the control group,and the prevalence of metabolic syndrome in people with fatty liver was also higher than that in the control group.Conclusion The prevalence of fatty liver and metabolic syndrome were 12.3% and 13.6% respectively in ZRCC.Fatty liver is the accumulation of risk factors of metabolic syndrome.
Cite
Citations (0)
Background. Fatty liver index (FLI) and lipid accumulation product (LAP) are indexes originally designed to assess the risk of fatty liver and cardiovascular disease, respectively. Both indexes have been proven to be reliable markers of subsequent metabolic syndrome; however, their ability to predict metabolic syndrome in subjects without fatty liver disease has not been clarified. Methods. We enrolled consecutive subjects who received health check-up services at Taipei Veterans General Hospital from 2002 to 2009. Fatty liver disease was diagnosed by abdominal ultrasonography. The ability of the FLI and LAP to predict metabolic syndrome was assessed by analyzing the area under the receiver operating characteristic (AUROC) curve. Results. Male sex was strongly associated with metabolic syndrome, and the LAP and FLI were better than other variables to predict metabolic syndrome among the 29,797 subjects. Both indexes were also better than other variables to detect metabolic syndrome in subjects without fatty liver disease (AUROC: 0.871 and 0.879, resp.), and the predictive power was greater among women. Conclusion. Metabolic syndrome increases the cardiovascular disease risk. The FLI and LAP could be used to recognize the syndrome in both subjects with and without fatty liver disease who require lifestyle modifications and counseling.
Liver disease
Cite
Citations (27)
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Kłujszo E, Parcheta P, Witkowska A, Kręcisz B. Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(4):468-474. doi:10.5114/ada.2019.83983. APA Kłujszo, E., Parcheta, P., Witkowska, A., & Kręcisz, B. (2020). Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(4), 468-474. https://doi.org/10.5114/ada.2019.83983 Chicago Kłujszo, Elżbieta Halina, Piotr Parcheta, Anna B. Witkowska, and Beata Kręcisz. 2020. "Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 37 (4): 468-474. doi:10.5114/ada.2019.83983. Harvard Kłujszo, E., Parcheta, P., Witkowska, A., and Kręcisz, B. (2020). Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 37(4), pp.468-474. https://doi.org/10.5114/ada.2019.83983 MLA Kłujszo, Elżbieta Halina et al. "Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 37, no. 4, 2020, pp. 468-474. doi:10.5114/ada.2019.83983. Vancouver Kłujszo E, Parcheta P, Witkowska A, Kręcisz B. Non-alcoholic Fatty liver Disease in Patients with Psoriasis - Therapeutic Implications. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2020;37(4):468-474. doi:10.5114/ada.2019.83983.
Alcoholic fatty liver
Cite
Citations (16)
Metabolic syndrome (MS) and Non-Alcoholic Fatty Liver Disease (NAFLD) spectrum disorder share commonrisk factors namely obesity, hypertension, diabetes mellitus, and dyslipidemia, and hence, there is evidencenow to show that NAFLD may actually be a hepatic manifestation of MS. Moreover, the presence of NAFLDin a patient with metabolic syndrome increases the risk of cardiovascular events and other co-morbidities.Hence there is a need to develop an integrated preventive and therapeutic approach for both these conditionsand not treat them as separate entities.
Dyslipidemia
Cite
Citations (0)
Concomitant
Cite
Citations (1)
Steatohepatitis
Steatosis
Cite
Citations (1,116)
In Western world, non-alcohlic fatty liver disease (NAFLD) is considered to be the commonest liver problem, and it is being recognised as a major cause of liver-related morbidity and mortality. As the prevalence of overweight/obesity and metabolic syndrome increases, NASH may become one of the more common causes of end stage liver disease and hepatocellular carcinoma. But much information is not available in this association. So an attempt has been made to correlate both.
Liver disease
Cite
Citations (12)
Non-alcoholic fatty liver disease (NAFLD) is considered to be the commonest liver problem in the western world and is increasingly being recognised as a major cause of liver-related morbidity and mortality. It is known to be associated with various metabolic abnormalities, but not much information regarding association between the metabolic disease and the severity of fatty liver is available.To study the clinical profile of patients of NAFLD with varying degrees of severity as diagnosed by ultrasonography and to study the correlation between the non-alcoholic fatty liver disease and metabolic syndrome along with its individual components.The study was an observational and analytical study of patients diagnosed as NAFLD, attending OPD and indoor patients of the Department of Medicine, J A Group of hospitals. All patients diagnosed as NAFLD were investigated for metabolic syndrome according to the NCEP ATP 3 Criteria and a relationship between NAFLD and metabolic syndrome was studied.51.4% of patients of NAFLD had metabolic syndrome and statistical significance was found in AST, diabetes mellitus and lipid profile.There is higher prevalence of all the components of metabolic syndrome in cases of NAFLD. Its early detection will help in modifying the disease course, delaying complications and will also play a major role in preventive cardiology.
Lipid Profile
Cite
Citations (19)
Non alcoholic fatty liver disease (NAFLD) is defined as fat accumulation exceeding 5% to 10% by the weight of the liver, in the absence of other causes of steatosis. NAFLD is strongly associated with metabolic diseases, such as metabolic syndrome. At present, insulin resistance, elevated concentrations of free fatty acids and oxidants, and an imbalance between different cytokines have been identified as the common pathophysiological elements underlying both NAFLD and metabolic syndrome. Emerging evidence also considers NAFLD as the hepatic manifestation of metabolic syndrome and supports a possible direct role of fat liver in cardiovascular risk assessment. Further investigations are needed to better understand the role of NAFLD, as an independent active factor in metabolic syndrome and associated cardiovascular disease. Keywords: Atherosclerosis, metabolic syndrome, non-alcoholic fatty liver disease, cardiovascular risk
Steatosis
Cite
Citations (17)